Tradestie Institutional Equity Comparison Engine

ABIG vs BOLD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BOLD Overall Edge

BOLD Captures Institutional Edge (2โ€“0 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Boundless Bio, Inc. Common Stock (BOLD) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, ABIG trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus BOLD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ABIG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ABIG N/M vs BOLD N/M Fwd P/E
Growth & Margin Winner BOLD
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner BOLD
1Y +1.3% vs +101.7% ยท 52W Pos 41% vs 62%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ABIG NASDAQ
Argent Large Cap ETF
Institutional Equity
$31.73
-3.67% 1D
Market Cap N/A
1M Return -9.65%
1Y Return +1.31%
Forward P/E N/M
Unified AI Score
46.8 / 100 HOLD
Tech 36.0 Fund 48.0 Flow 50.0 Mom 60.0
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
1M Return -4.92%
1Y Return +101.74%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABIG +1.31% BOLD +101.74% Spread: +100.15 pp (BOLD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABIG TTM Op. Margin: N/A BOLD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABIG vs BOLD. Trailing 12-month operating profitability (ABIG N/A vs BOLD 0.0%) and valuation multiples (ABIG N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABIG (2) vs BOLD (6)
Institutional Metric ABIG BOLD Criterion Row Winner
Market Capitalization Scale N/A $56.2M Larger Scale BOLD
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth BOLD
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin BOLD
Net Profit Margin Profitability N/A 0.0% Higher Margin BOLD
Return on Equity (ROE) Capital Efficiency N/A -64.6% Higher ROE BOLD
52-Week Range Position Momentum 41% ($28โ€“$36) 62% ($1โ€“$3) Stronger Trend BOLD
Beta / 30D Volatility Risk Regime 1.00ฮฒ ยท 22% Vol -0.08ฮฒ ยท 28% Vol Lower Realized Risk ABIG
Unified Institutional Score Composite Signal 46.8 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite ABIG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABIG vs BOLD Buy Guide
ABIG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ABIG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BOLD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABIG nor BOLD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.